Reference:USA 21 CFR Part 320 09-Apr-2025 § 320.22
From GxPlex
| Document information | |
|---|---|
| Reference | USA 21 CFR Part 320 09-Apr-2025 |
| Validity area | USA |
| Scope(s) | HM |
| Document name | 21 CFR Part 320 |
| Version / Revision | 09-Apr-2025 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | Title 21 —Food and Drugs
Chapter I —Food and Drug Administration, Department of Health and Human Services Subchapter D—Drugs for Human Use Part 320 Bioavailability and Bioequivalence Requirements https://www.ecfr.gov/current/title-21 |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 1 — Unit 1.2.2 |
| Scope | HM |
| Document part | § 320.22 |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | FDA, Requirements, Medicinal product |
| Comment | Criteria for waiver of in vivo bioavailability/bioequivalence evidence |
Content
§ 320.22 Criteria for waiver of evidence of in vivo bioavailability or bioequivalence. […]
